Dermapharm's 2025 revenue dips 1.3% as profitability climbs post-strategy shift

Dermapharm has reported a slight drop in revenue for 2025, with group sales falling by 1.3% to €1.165 billion. The decline follows the company's decision to exit low-margin products in its parallel import business. Despite this, adjusted earnings rose, and a major share buyback programme is now underway.

The pharmaceutical group's total revenue reached approximately €1.2 billion, down from the previous year. A key factor was the withdrawal from unprofitable parallel import deals with Axicorp, which weighed on overall sales. However, this move also improved profitability, lifting adjusted EBITDA by 2.9% to €324.8 million.

The company's EBITDA margin grew by 1.2 percentage points, climbing to 27.9%. While the 'other health products' division—home to brands like Euromed and Anton Hübner—held steady, Arkopharma experienced a downturn. Organic growth in branded pharmaceuticals helped soften the revenue decline but did not fully cover the losses. Looking ahead, Dermapharm's executive and supervisory boards have greenlit a public share repurchase offer. The plan involves buying back up to 4.3 million shares at €42 each. The finalised annual report, including confirmed figures, will be published on March 31.

Dermapharm's strategic shift away from low-margin imports has trimmed revenue but strengthened earnings. The share buyback programme signals confidence in the company's financial position. Full details of the 2025 performance will be released at the end of March.